130 256

Cited 10 times in

A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high-dose chemotherapy with autologous stem cell rescue.

Authors
 Sung Jin Hong  ;  Jin Seok Kim  ;  Jong Hee Chang  ;  Kyoung Min Kim  ;  Soo Jeong Kim  ;  Hye Won Lee  ;  June-Won Cheong  ;  Seung Tae Lee  ;  Yoo Hong Min 
Citation
 YONSEI MEDICAL JOURNAL, Vol.50(2) : 280-283, 2009 
Journal Title
 YONSEI MEDICAL JOURNAL 
ISSN
 0513-5796 
Issue Date
2009
MeSH
Antibodies, Monoclonal/therapeutic use* ; Antibodies, Monoclonal, Murine-Derived ; Central Nervous System Neoplasms/drug therapy* ; Central Nervous System Neoplasms/therapy* ; Cytarabine/therapeutic use ; Etoposide/therapeutic use ; Female ; Humans ; Ifosfamide/therapeutic use ; Lymphoma, Non-Hodgkin/drug therapy* ; Lymphoma, Non-Hodgkin/therapy* ; Middle Aged ; Rituximab ; Stem Cell Transplantation/methods*
Keywords
Primary central nervous system lymphoma ; high-dose chemotherapy with autologous stem cell rescue ; rituximab ; salvage therapy
Abstract
The prognosis for patients with primary central nervous system (CNS) lymphoma (PCNSL) who relapse after the initial response is usually poor. A standard treatment for relapsed PCNSL has not yet been identified because of the heterogeneity of the therapies employed and the lack of large, prospective clinical trials. We describe a 46-year-old relapsed PCNSL patient who was successfully treated with intraventricular applications of rituximab to minimize neurotoxicity, 2 cycles of salvage chemotherapy with etoposide, ifosfamide, and cytarabine (VIA) regimen and high-dose chemotherapy with autologous stem cell rescue. The high-dose chemotherapy consisted of bischloroethylnitrosourea, etoposide, cytarabine, and melphalan (BEAM) regimen. Partial remission was detected after intraventricular rituximab therapy and the patient has been in complete remission without evidence of neurotoxicity for 28 months after high-dose chemotherapy with autologous stem cell rescue. This case indicates a new appropriate treatment guideline in relapsed PCNSL patient after initial intensive chemo-radiotherapy.
Files in This Item:
T200903228.pdf Download
DOI
10.3349/ymj.2009.50.2.280
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurosurgery (신경외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Kyung Rae(김경래)
Kim, Soo Jeong(김수정) ORCID logo https://orcid.org/0000-0001-8859-3573
Kim, Jin Seok(김진석) ORCID logo https://orcid.org/0000-0001-8986-8436
Min, Yoo Hong(민유홍) ORCID logo https://orcid.org/0000-0001-8542-9583
Chang, Jong Hee(장종희)
Cheong, June-Won(정준원) ORCID logo https://orcid.org/0000-0002-1744-0921
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/104796
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse